Primair centraal zenuwstelsel non-Hodgkin lymfoom

5
10
15
20
25
30
35
40
45
50
35. Schultz C, Scott C, Sherman W, Donahue B, Fields J, Murray K, et al. Preirradiation
chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone
for primary CNS lymphomas: initial report of radiation therapy oncology group
protocol 88-06. J Clin Oncol 1996; 14:556-64.
36. Ferreri AJ, Reni M, Villa E. Therapeutic management of primary central nervous
system lymphoma: lessons from prospective trials. Ann Oncol 2000; 11:927-37.
37. Freilich RJ, Delattre JY, Monjour A, DeAngelis LM. Chemotherapy without radiation
therapy as initial treatment for primary CNS lymphoma in older patients. Neurology
1996; 46:435-9.
38. Neuwelt EA, Goldman DL, Dahlborg SA, Crossen J, Ramsey F, Roman-Goldstein S,
et al. Primary CNS lymphoma treated with osmotic blood-brain barrier disruption:
prolonged survival and preservation of cognitive function. J Clin Oncol 1991; 9:1580-
90.
39. Soussain C, Suzan F, Hoang-Xuan K, Cassoux N, Levy V, Azar N, et al. Results of
intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients
with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin
Oncol 2001; 19:742-9.
40. Reni M, Ferreri AJ, Villa E. Second-line treatment for primary central nervous system
lymphoma. Br J Cancer 1999; 79:530-4.
41. Herrlinger U, Schabet M, Brugger W, Kortmann RD, Kanz L, Bamberg M, et al.
Primary central nervous system lymphoma 1991-1997: outcome and late adverse
effects after combined modality treatment. Cancer 2001; 91:130-5.
42. Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. J
Clin Oncol 1998; 16:859-63.
43. Litam JP, Cabanillas F, Smith TL, Bodey GP, Freireich EJ. Central nervous system
relapse in malignant lymphomas: risk factors and implications for prophylaxis. Blood
1979; 54:1249-57.
44. Levitt LJ, Dawson DM, Rosenthal DS, Moloney WC. CNS involvement in the non-
Hodgkin's lymphomas. Cancer 1980; 45:545-52.
45. Ersboll J, Schultz HB, Thomsen BL, Keiding N, Nissen NI. Meningeal involvement in
non-Hodgkin's lymphoma: symptoms, incidence, risk factors and treatment. Scand J
Haematol 1985; 35:487-96.
46. Mead GM, Kennedy P, Smith JL, Thompson J, Macbeth FR, Ryall RD, et al.
Involvement of the central nervous system by non-Hodgkin's lymphoma in adults. A
review of 36 cases. Q J Med 1986; 60:699-714.
47. Hoerni-Simon G, Suchaud JP, Eghbali H, Coindre JM, Hoerni B. Secondary
involvement of the central nervous system in malignant non-Hodgkin's lymphoma. A
study of 30 cases in a series of 498 patients. Oncology 1987; 44:98-101.
48. Liang R, Chiu E, Loke SL. Secondary central nervous system involvement by non-
Hodgkin's lymphoma: the risk factors. Hematol Oncol 1990; 8:141-5.
49. Keldsen N, Michalski W, Bentzen SM, Hansen KB, Thorling K. Risk factors for central
nervous system involvement in non-Hodgkins-lymphoma--a multivariate analysis.
Acta Oncol 1996; 35:703-8.
50. Bos GM, van Putten WL, van der Holt B, van den Bent M, Verdonck LF, Hagenbeek
A. For which patients with aggressive non-Hodgkin's lymphoma is prophylaxis for
central nervous system disease mandatory? Dutch HOVON Group. Ann Oncol 1998;
9:191-4.
51. Hollender A, Kvaloy S, Nome O, Skovlund E, Lote K, Holte H. Central nervous
system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model.
Ann Oncol 2002; 13:1099-107.
52. Bollen EL, Brouwer RE, Hamers S, Hermans J, Kluin M, Sankatsing SU, et al. Central
nervous system relapse in non-Hodgkin lymphoma. A single-center study of 532
patients. Arch Neurol 1997; 54:854-9.
CZS LYMFOMEN 13